Search for a trial

Smellprints in lung Cancer; the role of ENose in diagnosis and Treatment (SCENT):
part 1. Differences in smellprints between patients with lung cancer and breast cancer

Primairy objective: we will examine the difference in VOC pattern of exhaled air between patients with histology-confirmed diagnoses of non small cell lung cancer vs breast cancer. Secundairy objective: a. to confirm the potential of the electronic…

High Definition bronchoscopy, an exploratory study of diagnostic value in comparison to standard white light bronchoscopy and autofluorescence bronchoscopy

(1) Investigate diagnostic performance (sensitivity) of HD bronchoscopy, with or without surface enhancement or tone enhancement in comparison to standard WLB for detecting abnormalities of the tracheobronchial tree. Furthermore we aim to…

Arm function and quality of life after trimodal treatment of sulcus superior tumour (SST)

Determine arm and shoulder function and quality of life scores before and after treatment of SST. The untreated extremity can serve as a control.Determine riskfactors for a poor functionale outcome and quality of life after treatment for SST (e.g.…

LUME-Lung 3. A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology.

Run-in phase I: To confirm the safety and tolerability of BIBF 1120 up to a dose level of 200 mg b.i.d added to a standard dose of cisplatin/gemcitabine in first line NSCLC patients with squamous cell histology. Pharmacokinetics of BIBF 1120 and…

Brown adipose tissue activity in lung cancer

To study the effect of early tumour development on brown adipose tissue activity

Observational study into specific in vivo human discrimination between benign and malignant tissue using a combination of Diffuse Reflectance and Fluorescence spectroscopy

Aim of this study is to confirm the results from ex vivo research in humans in a clinical setting. The objective is to perform optical spectroscopy measurements during surgical procedures in vivo, involving resection of either breast, liver or lung…

An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway.

The purpose of this prospective, multi-center, open-label, two-stage phase II study is to assessthe efficacy of BKM120, as measured by determining the PFS, in patients with pretreatedmetastatic NSCLC that exhibits PI3K pathway activation. BKM120…

Evaluation of molecular sputum test diagnostic for lung cancer

Establish the clinical value of a molecular sputum test for the diagnosis of lung cancer.

PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC;LYMPHOMA KINASE (ALK) GENE LOCUS

To demonstrate that crizotinib (Arm A) is superior to first-line chemotherapy, pemetrexed/cisplatin or pemetrexed/carboplatin (Arm B), in prolonging PFS in patients with advanced non-squamous NSCLC whose tumors harbor a translocation or inversion…

A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared with Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Nonsmall Cell Lung Cancer (MEK114653)

Primary: progression-free survival in the GSK1120212-group in comparison with the docetaxel group. Secondary: safety and tolerability, response rate, duration of response, overall survival, PK.

Chloroquine as an anti-autophagic chemosensitizing drug in stage IV small cell lung cancer (SCLC) patients: A phase I trial.

To determine the toxicity of adding chloroquine in escalating doses in patients with small cell lung cancer to standard therapy.

An Open-label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

Primary ObjectiveTo compare the objective response rate and overall surival of BMS-936558 versus docetaxel in subjects with squamous cell NSCLC after failure of prior platinum-based chemotherapySecondary ObjectivesTo compare the progression-free…

Recovery of Physical and Psychological health, and Health-Related Quality of Life (HRQoL) in lung cancer patients six months following lung resection.

The main aim of this study is to explore the recovery of physical and psychological health status, and HRQoL simultaneously in lung cancer patients that have undergone lung resection in the Netherlands. Next to that, we hope to identify the…

A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib

The primary objective of this study is to evaluate the overall response rate (ORR) of LY2875358 plus erlotinib therapy and LY2875358 monotherapy in patients with met proto-oncogene (hepatocyte growth factor receptor) (MET) diagnostic positive (MET…

A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer (NITRO TRIAL, NVALT-21 study)

To determine the efficacy and safety of adding transdermal nitroglycerin to first line chemotherapy for advanced NSCLC.

A diagnostic Study of European and Japanese advanced NSCLC patients to evaluate suitable sample types for EGFR testing: The ASSESS Study

This study will investigate if it is possible to perform the EGFR mutation test using blood samples. If successful, this study may mean that in the future, the mutation test can be done using a blood sample, and that patients may not need to have…

A phase II study of gefitinib and fulvestrant in patients with advanced EGFR mutated non small cell lung cancer pretreated with reversible EGFR tyrosine kinase inhibitors

2.1 Primary objectiveTo assess the rate of no progression (NPR) at 8 weeks following treatment with the combination of gefitinib and fulvestrant in EGFR mutated patients who failed previous treatment with reversible EGFR TKI*s (gefitinib or…

A phase II, multi-center, open-label study of AUY922 administered i.v. on a once-weekly schedule in patients with advanced non-small-cell lung cancer who have received at least two lines of prior chemotherapy

Primary objective* To estimate efficacy for each study stratum at 18 weeks as assessed by RECISTKey Secondary objectives:* To estimate overall survival (OS) and progression free survival (PFS) in patients with advanced NSCLC* To determine safety and…

Video-assisted thoracic surgery versus open lobectomy for lung cancer: a randomized prospective trial

To compare quality of life, cost-effectivenessand number of dissected mediastinal lymph node as a derivative oncologic outcome between open- and VATS lobectomy.

Response evaluation after chemoradiation for advanced oropharyngeal cancer using PET-CT and MRI

To study the value of MRI and 18FDG-PET-CT in the detection of local residual oropharyngeal disease after chemoradiation to avoid futile routine examination under general anesthesia.